• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet

Insulet rises on Street-beating Q4 revenues

February 24, 2021 By Sean Whooley

Insulet

Insulet (NSDQ:PODD) shares rose before the market opened today on fourth-quarter results that beat the consensus revenue forecast. The Acton, Mass.-based wearable insulin delivery system developer posted losses of -$17.1 million, or -26¢ per share, on sales of $246.1 million for the three months ended Dec. 31, 2020, for a bottom-line slide into the red on […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Insulet

Global wearable patch market growing at 10.6% rate

February 22, 2021 By Sean Whooley

G6

Researchers say that the global wearable patch market size is expected to reach $12.6 billion by 2026, marking a massive rise over five years. According to the research, put together by ResearchAndMarkets.com, the rise is expected to represent a compound annual growth rate of 10.6% during the forecast period. Wearables covered by the research, including […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: abbott, Dexcom, Eli Lilly & Co., Insulet, sanofi, wearables

Insulet surpasses Q3 earnings estimates, raises guidance

November 5, 2020 By Brian Buntz

Insulet

Insulet (NSDQ:PODD) posted third-quarter results after market close yesterday that beat analysts’ consensus for the company. The Acton, Mass.-based tubeless insulin pump manufacturer announced profits of $11.6 million or $0.17 per share on sales of $234 million for the three months ended September 30, 2020, for a bottom-line gain of 13.5% on sales growth of 21% compared […]

Filed Under: Diabetes, Featured, MassDevice Earnings Roundup Tagged With: Insulet

Insulet up on Street-beating Q2, raised guidance

August 7, 2020 By Sean Whooley

Insulet

Insulet (NSDQ:PODD) shares ticked up today on second-quarter results that topped the consensus forecast. The Acton, Mass.-based wearable insulin delivery system developer posted profits of $14.4 million, or 22¢ per share, on sales of $226.3 million for the three months ended June 30, 2020, for a bottom-line gain of nearly ten times as much as last […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: coronavirus, COVID-19, Insulet

Insulet installs thousands of solar panels at global HQ

June 24, 2020 By Sean Whooley

Insulet (NSDQ:PODD) announced today that its corporate headquarters and manufacturing facility will be powered by solar-based, renewable energy. The Acton, Mass.-based facility is set to turn to the new energy source, beginning this week. The company covered its 58,000 square-foot manufacturing facility with approximately 2,800 solar panels to, during optimal climate conditions, generate enough energy to […]

Filed Under: Business/Financial News, Diabetes Tagged With: Insulet

Insulet resumes next-gen Omnipod pivotal study following software issues

June 5, 2020 By Danielle Kirsh

Insulet

Insulet (NSDQ:PODD) today said it has resumed its pivotal study of its next-generation Omnipod Insulin Management System after pausing the study in March due to a software anomaly. The company paused the study about halfway through completion to correct an issue that could result in the system using an incorrect glucose value that had the potential to impact […]

Filed Under: Diabetes Tagged With: Insulet

DHS warns on Insulet Omnipod

March 23, 2020 By Sean Whooley

Insulet

The U.S. Dept. of Homeland Security (DHS) issued a medical advisory to warn of vulnerabilities with the Insulet (NSDQ:PODD) Omnipod insulin management system. According to the advisory, the affected insulin pumps are designed to communicate using a wireless RF with Insulet’s personal diabetes manager device, but the RF communication protocol does not properly implement authentication or authorization. […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Cybersecurity, Insulet

Insulet down after hours on Q4 sales beat, bottom-line slide

February 25, 2020 By Sean Whooley

Insulet

Insulet (NSDQ:PODD) shares sunk after hours today on fourth-quarter results that beat the consensus forecast for revenue but appeared to miss on earnings. The Acton, Mass.–based insulin delivery device maker posted profits of $5 million, or 8¢ per share, on sales of $209.4 million for the three months ended Dec. 31, 2019, for a 49.5% bottom-line […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Insulet

Insulet partners with Abbott and Dexcom on automated insulin delivery

February 19, 2020 By Sean Whooley

Abbott (NYSE:ABT) and Dexcom (NSDQ:DXCM) each announced today that they are partnering with Insulet (NSDQ:PODD) to feed blood glucose monitor data into an automated insulin delivery system. For Acton, Mass.–based Insulet, the agreements are a boost for its next-generation Omnipod Horizon automated insulin delivery system, which is presently an investigational device in the United States.  The idea of an “artificial […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: abbott, Dexcom, Insulet

Insulet’s Omnipod Dash Personal Diabetes Managers have a glitch

February 13, 2020 By Chris Newmarker

Insulet Ominipod Dash Personal Diabetes Managers

Insulet (NSDQ:PODD) is issuing a voluntary medical device correction for all of the smartphone-like Personal Diabetes Managers that came with its next-gen Omnipod Dash insulin management system, the company announced today. During its ongoing quality management process, Insulet officials discovered that the PDMs on rare occasions will suggest an inaccurate bolus amount based on a blood […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, mHealth (Mobile Health), Recalls Tagged With: Insulet, insulin

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 8
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS